China Regenerative Medicine International Limited Fundamental Analysis
China Regenerative Medicine International Limited Fundamental Analysis
China Regenerative Medicine International Limited (8158.HK) shows strong financial fundamentals with a PE ratio of 3.53, profit margin of 38.20%, and ROE of 80.48%. The company generates $0.1B in annual revenue with N/A year-over-year growth of N/A.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 63.9/100 based on profitability, valuation, growth, and balance sheet metrics. The C+ grade reflects average fundamentals, with notable risks in certain areas.
Fundamental Health Score
We analyze 8158.HK's fundamental strength across five key dimensions:
Efficiency Score
Excellent8158.HK demonstrates superior asset utilization.
Valuation Score
Excellent8158.HK trades at attractive valuation levels.
Growth Score
Weak8158.HK faces weak or negative growth trends.
Financial Health Score
Excellent8158.HK maintains a strong and stable balance sheet.
Profitability Score
Moderate8158.HK maintains healthy but balanced margins.
Key Financial Metrics
Is 8158.HK Expensive or Cheap?
P/E Ratio
8158.HK trades at 3.53 times earnings. This suggests potential undervaluation.
PEG Ratio
When adjusting for growth, 8158.HK's PEG of 0.06 indicates potential undervaluation.
Price to Book
The market values China Regenerative Medicine International Limited at 1.82 times its book value. This may indicate undervaluation.
EV/EBITDA
Enterprise value stands at 6.56 times EBITDA. This is generally considered low.
How Well Does 8158.HK Make Money?
Net Profit Margin
For every $100 in sales, China Regenerative Medicine International Limited keeps $38.20 as profit after all expenses.
Operating Margin
Core operations generate -2.21 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $80.48 in profit for every $100 of shareholder equity.
ROA
China Regenerative Medicine International Limited generates $16.38 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
China Regenerative Medicine International Limited generates limited operating cash flow of $-6.25M, signaling weaker underlying cash strength.
Free Cash Flow
China Regenerative Medicine International Limited generates weak or negative free cash flow of $-6.56M, restricting financial flexibility.
FCF Per Share
Each share generates $-0.02 in free cash annually.
FCF Yield
8158.HK converts -6.74% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
3.53
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
0.06
vs 25 benchmark
P/B Ratio
Price to book value ratio
1.82
vs 25 benchmark
P/S Ratio
Price to sales ratio
1.35
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
0.96
vs 25 benchmark
Current Ratio
Current assets to current liabilities
1.14
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
0.80
vs 25 benchmark
ROA
Return on assets percentage
0.16
vs 25 benchmark
ROCE
Return on capital employed
-0.02
vs 25 benchmark
How 8158.HK Stacks Against Its Sector Peers
| Metric | 8158.HK Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | 3.53 | 29.63 | Better (Cheaper) |
| ROE | 80.48% | 223.00% | Weak |
| Net Margin | 38.20% | -38669.00% (disorted) | Strong |
| Debt/Equity | 0.96 | 0.82 | Neutral |
| Current Ratio | 1.14 | 4.30 | Neutral |
| ROA | 16.38% | -379.00% (disorted) | Strong |
8158.HK outperforms its industry in 3 out of 6 key metrics, particularly excelling in Net Margin, but lagging in ROE.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews China Regenerative Medicine International Limited's 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
N/A
Industry Style: Defensive, Growth, Innovation
EPS CAGR
N/A
Industry Style: Defensive, Growth, Innovation
FCF CAGR
N/A
Industry Style: Defensive, Growth, Innovation